slides · global inventory
Disclaimer
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,127
Current window 32,701-32,730
Pages 1,371
Rows per page 30
Component
32,701-32,730 of 41,127
03
Factset | Results Presentation Deck | 22 slidesFactset | Results Presentation Deck | 22 slides · FactSet
Conference presentation Investor relations 1 hit
11
The slide includes a disclaimer regarding forward-looking statements and a footnote defining the first row metric.Factset | Results Presentation Deck | 22 slides · FactSet
Conference presentation Investor relations 1 hit
16
Includes footnote regarding calculation of adjusted operating margin.Factset | Results Presentation Deck | 22 slides · FactSet
Conference presentation Investor relations 1 hit
20
The slide provides a forward-looking reconciliation for FactSet's FY2024 business outlook.Factset | Results Presentation Deck | 22 slides · FactSet
Conference presentation Investor relations 1 hit
02
FGI Industries | Investor Presentation Deck | 30 slidesFGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations 1 hit
26
Includes a disclaimer regarding the basis of the adjusted figures and specific investment costs.FGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · Financials1 hit
02
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
11
The slide uses a table to compare clinical outcomes across patient subgroups (all, resistant, refractory) and a callout box for key takeaways.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
03
Includes a disclaimer regarding non-GAAP metrics at the bottom.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · Attention1 hit
07
Includes footnotes detailing reconciliation and definitions.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
18
Includes footnotes regarding unamortized discounts and deferred financing costs.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 62 slidesImmix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Situation & Context1 hit
06
Includes a B-cell development diagram and a human anatomy map linking specific diseases to medical specialties.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
18
The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-day mark.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
19
The slide uses a bottom-up summation approach to define the total eligible patient pool.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
28
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
32
The table uses a cross-trial comparison format. The red dashed box highlights the key clinical data rows.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
35
The chart illustrates clinical trial efficacy data for NXC-201.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
39
The slide uses a comparative layout to position NXC-201 as a superior, one-time monotherapy against current multi-drug, weekly treatment regimens.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
41
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management of side effects.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
49
Includes unpublished internal data alongside referenced Winograd et al. 2015 study.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
50
The slide compares two cohorts: Soft Tissue Sarcoma and Non-Sarcoma Cancers, using line charts for longitudinal change and bar charts for best response.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
51
The slide uses a bubble chart to map clinical trial outcomes and a table to detail specific drug performance metrics across treatment lines.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
57
The slide compares efficacy benchmarks of established competitors (AbbVie, J&J, Takeda) to set a baseline for the IMX-120 opportunity.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
02
Innovid | Investor Day Presentation Deck | 74 slidesInnovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
03
Innovid | Investor Day Presentation Deck | 74 slidesInnovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
42
The chart illustrates a positive correlation between account tier (by revenue) and client tenure.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
64
Innovid | Investor Day Presentation Deck | 74 slidesInnovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
65
Innovid | Investor Day Presentation Deck | 74 slidesInnovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit